USD 1.41
(-0.28%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 24 Million USD | 104.71% |
2022 | 11.72 Million USD | -44.82% |
2021 | 21.24 Million USD | 50.13% |
2020 | 14.15 Million USD | 13.9% |
2019 | 12.42 Million USD | 58.07% |
2018 | 7.86 Million USD | 7.08% |
2017 | 7.34 Million USD | 90.35% |
2016 | 3.85 Million USD | 140.77% |
2015 | 1.6 Million USD | 172.52% |
2014 | 587.83 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 944 Thousand USD | -83.8% |
2024 Q1 | 5.82 Million USD | -21.77% |
2023 Q2 | 2.54 Million USD | -2.87% |
2023 Q4 | 7.45 Million USD | 225.19% |
2023 FY | 24 Million USD | 104.71% |
2023 Q1 | 2.61 Million USD | 16.62% |
2023 Q3 | 2.29 Million USD | -9.87% |
2022 FY | 11.72 Million USD | -44.82% |
2022 Q1 | 3.62 Million USD | -17.64% |
2022 Q4 | 2.24 Million USD | -37.87% |
2022 Q3 | 3.61 Million USD | 15.77% |
2022 Q2 | 3.12 Million USD | -14.0% |
2021 FY | 21.24 Million USD | 50.13% |
2021 Q4 | 4.4 Million USD | -15.04% |
2021 Q1 | 6.18 Million USD | 19.97% |
2021 Q2 | 5.47 Million USD | -11.6% |
2021 Q3 | 5.18 Million USD | -5.23% |
2020 Q2 | 3.24 Million USD | 10.78% |
2020 FY | 14.15 Million USD | 13.9% |
2020 Q1 | 2.93 Million USD | -10.86% |
2020 Q4 | 5.15 Million USD | 83.01% |
2020 Q3 | 2.81 Million USD | -13.15% |
2019 Q3 | 2.67 Million USD | -28.7% |
2019 Q4 | 3.28 Million USD | 23.11% |
2019 FY | 12.42 Million USD | 58.07% |
2019 Q1 | 2.72 Million USD | 114.6% |
2019 Q2 | 3.74 Million USD | 37.37% |
2018 Q3 | 2.73 Million USD | 13.49% |
2018 Q2 | 2.41 Million USD | 66.82% |
2018 FY | 7.86 Million USD | 7.08% |
2018 Q4 | 1.27 Million USD | -53.57% |
2018 Q1 | 1.44 Million USD | 83.17% |
2017 Q3 | 1.53 Million USD | -36.26% |
2017 FY | 7.34 Million USD | 90.35% |
2017 Q1 | 2.62 Million USD | 24.87% |
2017 Q4 | 788.88 Thousand USD | -48.45% |
2017 Q2 | 2.4 Million USD | -8.45% |
2016 Q3 | 8352.00 USD | -52.11% |
2016 Q4 | 2.1 Million USD | 25043.68% |
2016 Q1 | 3489.00 USD | -56.77% |
2016 Q2 | 17.43 Thousand USD | 399.83% |
2016 FY | 3.85 Million USD | 140.77% |
2015 Q2 | 4829.00 USD | 0.0% |
2015 Q4 | 8070.00 USD | 93.25% |
2015 Q3 | 4176.00 USD | -13.52% |
2015 FY | 1.6 Million USD | 172.52% |
2014 FY | 587.83 Thousand USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ANI Pharmaceuticals, Inc. | 195.98 Million USD | 87.753% |
Aquestive Therapeutics, Inc. | 44.85 Million USD | 46.488% |
Collegium Pharmaceutical, Inc. | 159.2 Million USD | 84.924% |
Cosmos Health Inc. | 26.18 Million USD | 8.322% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -14.067% |
Esperion Therapeutics, Inc. | 271.89 Million USD | 91.172% |
Cronos Group Inc. | 96.7 Million USD | 75.181% |
Incannex Healthcare Limited | 30.05 Million USD | 20.134% |
Kala Pharmaceuticals, Inc. | 39.15 Million USD | 38.697% |
Lifecore Biomedical, Inc. | 49.03 Million USD | 51.054% |
Regencell Bioscience Holdings Limited | 3.99 Million USD | -501.385% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -82.88% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -82.88% |
SCYNEXIS, Inc. | 51.84 Million USD | 53.707% |
Safety Shot Inc | 12.1 Million USD | -98.206% |
Theratechnologies Inc. | 72.75 Million USD | 67.01% |
Alpha Teknova, Inc. | 45.85 Million USD | 47.661% |
Universe Pharmaceuticals INC | 13.84 Million USD | -73.402% |
Pacira BioSciences, Inc. | 326.37 Million USD | 92.646% |
Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -154.098% |
Dynavax Technologies Corporation | 219.14 Million USD | 89.047% |
Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 89.66% |
Radius Health, Inc. | 265.92 Million USD | 90.974% |
China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -682.034% |
Alvotech | 285.43 Million USD | 91.591% |
Intra-Cellular Therapies, Inc. | 590 Million USD | 95.932% |
SIGA Technologies, Inc. | 22.04 Million USD | -8.887% |
Shineco, Inc. | 17.94 Million USD | -33.731% |
Silver Spike Investment Corp. | 762.49 Thousand USD | -3047.848% |
Journey Medical Corporation | 54.59 Million USD | 56.035% |
Petros Pharmaceuticals, Inc. | 17.8 Million USD | -34.779% |
Embecta Corp. | 528.4 Million USD | 95.458% |
Harrow Health, Inc. | 89.97 Million USD | 73.323% |
Procaps Group, S.A. | 199.47 Million USD | 87.967% |
Biofrontera Inc. | 39.95 Million USD | 39.933% |
DURECT Corporation | 43.71 Million USD | 45.094% |
PainReform Ltd. | 9.58 Million USD | -150.439% |
Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 95.463% |
OptiNose, Inc. | 85.1 Million USD | 71.796% |
RedHill Biopharma Ltd. | -9.56 Million USD | 351.042% |
Organogenesis Holdings Inc. | 314.13 Million USD | 92.359% |
Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 44.234% |
ProPhase Labs, Inc. | 37.85 Million USD | 36.59% |
Phibro Animal Health Corporation | 260.29 Million USD | 90.779% |
Procaps Group S.A. | 187.24 Million USD | 87.181% |
TherapeuticsMD, Inc. | 9.82 Million USD | -144.296% |
Viatris Inc. | 5.96 Billion USD | 99.598% |
Rockwell Medical, Inc. | 15.37 Million USD | -56.121% |
Aytu BioPharma, Inc. | 59.84 Million USD | 59.89% |
Tilray Brands, Inc. | 251.35 Million USD | 90.451% |
PetIQ, Inc. | 192.72 Million USD | 87.546% |
Talphera, Inc. | 11.99 Million USD | -100.117% |
Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.497% |
Alimera Sciences, Inc. | 62.64 Million USD | 61.683% |
Assertio Holdings, Inc. | 368.58 Million USD | 93.488% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -307.812% |
Avadel Pharmaceuticals plc | 164.96 Million USD | 85.45% |
Hempacco Co., Inc. | 7.59 Million USD | -215.965% |
Alvotech | 285.43 Million USD | 91.591% |
Lantheus Holdings, Inc. | 344.9 Million USD | 93.041% |
Kamada Ltd. | 45.42 Million USD | 47.162% |
Indivior PLC | 911 Million USD | 97.365% |
Evoke Pharma, Inc. | 12.4 Million USD | -93.415% |
Flora Growth Corp. | 10.57 Million USD | -126.884% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -14.067% |
Evolus, Inc. | 189.75 Million USD | 87.351% |
HUTCHMED (China) Limited | 436.23 Million USD | 94.498% |
Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 84.428% |
Akanda Corp. | 3.48 Million USD | -589.021% |